Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

1,272

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

May 31, 2008

Conditions
Malaria
Interventions
DRUG

Pyronaridine artesunate

Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)

DRUG

Coartem® (artemether lumefantrine)

AL (20:120mg tablets) twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)

Trial Locations (10)

86113

RSUD TC Hillers, Maumere

Unknown

Ecole de Santé Publique, Faculté de Médecine, Université de Kinshasa, Kinshasa

Komfo Anoykye Teaching Hospital, Kumasi

Jayapura General Hospital (RSUD) DOK II, Jayapura

Siaya District Hospital, Medical Superintendent's office, Siaya

Malaria Research and Training Center, Faculté de Médecine, de Pharmacie et d'Ondonto-stomatologie, Bamako

Instituto Nacional de Saude, Ministero de Saude, Maputo

Puerto Princesa General Hospital, Puerto Princesa City

Service de Parasitologie, Faculté de Médecine, Université Cheikh Anta Diop, Dakar

Farafenni Field Station, c/o: MRC Laboratories, Fajara

All Listed Sponsors
collaborator

Shin Poong Pharmaceuticals

INDUSTRY

lead

Medicines for Malaria Venture

OTHER

NCT00422084 - Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients | Biotech Hunter | Biotech Hunter